Midlothian, United Kingdom

Hayley Reece

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 3.7

ph-index = 2

Forward Citations = 4(Granted Patents)


Location History:

  • Scotland, GB (2017)
  • Midlothian, GB (2019)

Company Filing History:


Years Active: 2017-2019

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Hayley Reece: Innovator in Pharmaceutical Chemistry

Introduction

Hayley Reece is a notable inventor based in Scotland, GB, recognized for her significant contribution to pharmaceutical science. With a patent that demonstrates her innovative approach to tackling health issues, she has placed herself on the map as an influential figure in the development of therapeutic solutions.

Latest Patents

Hayley's most recent patent focuses on the "Crystalline forms of ponatinib hydrochloride." This patent involves the polymorphic forms of the hydrochloride salt of ponatinib and outlines the processes for their preparation. Moreover, it also discusses a pharmaceutical composition comprising these forms and their application in treating disorders associated with pathological cellular proliferation, including neoplasms and cancer. This patent marks a vital advancement in the pharmaceutical field, showcasing the potential of ponatinib in modern medicine.

Career Highlights

In her professional journey, Hayley has excelled at Sandoz AG, a prominent company in the pharmaceutical industry. Her dedication to innovation reflects not only in her patent but also in her ongoing efforts to improve treatment methodologies and patient outcomes.

Collaborations

Throughout her career, Hayley has worked alongside talented coworkers such as Marijan Stefinovic and Asha Sunkara. These collaborations have allowed for a rich exchange of ideas and research, contributing to enhanced research outcomes and innovative solutions in the field of pharmaceuticals.

Conclusion

Hayley Reece stands as a testament to the importance of innovation in healthcare, particularly through her groundbreaking patent on crystalline forms of ponatinib hydrochloride. Her contributions to Sandoz AG and her collaborative efforts with peers reflect her commitment to advancing pharmaceutical science, ultimately working toward improved therapies for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…